Secondary Data First: Discover how routinely collected healthcare data can be used to generate reliable evidence faster to address regulator, payer, and provider needs.

June 10, 2020

Sponsored Content

How routinely collected healthcare data can accelerate your real world evidence generation plan efficiently while minimizing burden on sites and patients. During this session you will have the opportunity to learn how secondary data can help address questions asked by different healthcare stakeholders and demonstrate safety, value, and effectiveness of your compound. Live: US: Wednesday, Jun. 10, 2020 10am EDT | 4pm CEST On demand available after airing until Jun. 10, 2021. Register free

Register free: http://www.pharmexec.com/pe_w/drug_lifecycle

Event Overview:
Secondary data sourced from routinely collected healthcare information is playing a decisive role in stakeholder decision making. Join us to learn how this data is accessed today, which database is right for your purposes, and the key steps you need to consider to optimize your studies from planning to execution. Discover more about:

  • Identifying the typical research questions across the drug lifecycle

  • Understanding what secondary data sources are fit for which purpose

  • Accessing clinically rich secondary data in rare diseases and oncology through novel solutions

  • Generating the right evidence for regulators, payers, providers, and patients 

We will share tangible examples of how multi-country database studies leveraging secondary data have helped answer key stakeholder questions throughout the product lifecycle. 

Speakers: Massoud Toussi, MD, PhD, MBA, Senior Principal, Real World Solutions, Paris, France, IQVIA

Nikita Jeswani, Principal, Real World Solutions, London, UK, IQVIA

Time and date: US: Wednesday, Jun. 10, 2020 10am EDT | 4pm CEST

On demand available after airing until Jun. 10, 2021.

Sponsor: IQVIA 

Register free: http://www.pharmexec.com/pe_w/drug_lifecycle